Excellent
Mostly Aligned
Patient Risk:
Low
Summary
All embryo-fetal toxicity/pregnancy counseling, contraception, hormonal contraceptive failure risk, and male/female reproductive potential counseling claims are supported by the provided FDA labeling excerpts.
Category Scores
Accurate Statements
WELIREG can cause fetal harm/embryo-fetal toxicity when administered to a pregnant woman (based on animal findings).
5.3 Embryo-Fetal Toxicity; 8.1 Pregnancy; 8.3 Females and Males of Reproductive Potential
Advise pregnant women and females of reproductive potential of the potential risk to the fetus.
5.3 Embryo-Fetal Toxicity; 8.1 Pregnancy; 17 Patient Counseling Information (Embryo-Fetal Toxicity)
Advise females of reproductive potential to use effective non-hormonal contraception during treatment with WELIREG and for 1 week after the last dose.
5.3 Embryo-Fetal Toxicity; 8.3 Females and Males of Reproductive Potential; 17 Patient Counseling Information (Embryo-Fetal Toxicity)
WELIREG can render some hormonal contraceptives ineffective / may lead to contraceptive failure or breakthrough bleeding.
7.2 Effect of WELIREG on Other Drugs (Hormonal contraceptives); 5.3 Embryo-Fetal Toxicity; 8.3 Females and Males of Reproductive Potential
Advise male patients with female partners of reproductive potential to use effective contraception during treatment with WELIREG and for 1 week after the last dose.
5.3 Embryo-Fetal Toxicity; 8.3 Females and Males of Reproductive Potential; 17 Patient Counseling Information (Embryo-Fetal Toxicity)
Unsupported Statements
Contradictions
Important Omissions
No inclusion of the label’s pregnancy-testing instruction for females of reproductive potential prior to initiating treatment (if the response was intended to be complete for reproductive counseling).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The provided claims align with label-required embryo-fetal toxicity counseling and contraception precautions; only a counseling-related omission (pregnancy testing prior to initiation) was identified.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Omitted label instruction to verify pregnancy status of females of reproductive potential prior to initiating treatment.
Suggested Improvement
Include the label’s pregnancy-testing step (verify pregnancy status prior to starting WELIREG) alongside the embryo-fetal toxicity counseling and contraception recommendations.